2024 年度募集资金存放与使用情况的专项核查意见 东方证券股份有限公司（以下简称"东方证券"或"保荐机构"）作为金河生物 科技股份有限公司（以下简称"金河生物"或"公司"）2021年非公开发行A股 股票并上市的保荐机构，根据《深圳证券交易所股票上市规则》《深圳证券交易 所上市公司自律监管指引第1号——主板上市公司规范运作》《深圳证券交易所 上市公司自律监管指引第13号——保荐业务》等有关法律法规和规范性文件的要 求，对金河生物2024年度募集资金的存放与使用情况进行了核查，具体情况如下： 一、募集资金基本情况 （一）募集资金到位情况 东方证券股份有限公司 关于金河生物科技股份有限公司 经中国证券监督管理委员会《关于核准金河生物科技股份有限公司非公开发 行股票的批复》（证监许可【2020】3344 号）核准，公司非公开发行人民币普 通股（A 股）145,132,743 股，每股面值人民币 1 元，发行价格为每股人民币 5.65 元，募集资金总额为人民币 819,999,997.95 元，扣除发行费用人民币 17,756,396.62 元后，实际募集资金净额为 802,243,601.33 元。信永中和会计师事 ...

内蒙古金河环保科技有限公司 业绩承诺利润实现情况审核报告 | 索引 | 页码 | | --- | --- | | 审核报告 | 1-2 | | 关于业绩承诺利润实现情况的说明 | 1-4 | 关于内蒙古金河环保科技有限公司 业绩承诺利润实现情况审核报告 XYZH/2025XAAA5B0177 金河生物科技股份有限公司 金河生物科技股份有限公司全体股东： 我们对后附的金河生物科技股份有限公司（以下简称"金河生物公司"）编制的《关 于内蒙古金河环保科技有限公司业绩承诺利润实现情况的说明》（以下简称"业绩承诺 说明"）执行了审核工作。 金河生物公司管理层的责任是按照深圳证券交易所发布的《深圳证券交易所上市公 司自律监管指引第 1 号——主板上市公司规范运作（2023 年 12 月修订）》编制业绩承 诺说明，并保证其内容真实、准确、完整，以及不存在由于舞弊或错误而导致的重大错 报。我们的责任是在实施审核工作的基础上，对业绩承诺说明发表审核意见。 我们按照《中国注册会计师其他鉴证业务准则第 3101 号--历史财务信息审计或审 阅以外的其他鉴证业务》的规定执行了审核工作，以对业绩承诺说明是否不存在重大错 报获取合理保证 ...

金河生物科技股份有限公司 2024 年度 非经营性资金占用及其他关联资金往来的 专项说明 | 索引 | 页码 | | --- | --- | | 专项说明 | 1-2 | | 非经营性资金占用及其他关联资金往来情况汇总表 | 1 | | 信永中和会计师事务所 北京市东城区朝阳门北大街 联系电话: +86(010) 6554 2288 | | | | --- | --- | --- | | telephone: +86 (010) 6554 2288 | 8 号富华大厦 A 座 9 层 | | | ShineWing | 9/F, Block A, Fu Hua Mansion, No.8, Chaoyangmen Beidajie, | +86 (010) 6554 7190 | | Dongcheng District, Beijing, 传真: | | | | certified public accountants 100027, P.R.China | | facsimile: +86 (010) 6554 7190 | 关于金河生物科技股份有限公司 2024 年度非经营性资金占用及其他关联资金往来的 ...

金河生物科技股份有限公司 2024 年度 内部控制审计报告 | 索引 | 页码 | | --- | --- | | 内部控制审计报告 | 1-2 | | 内部控制评价报告 | 1-8 | 内部控制审计报告 三、 内部控制的固有局限性 内部控制具有固有局限性，存在不能防止和发现错报的可能性。此外，由于情况的 变化可能导致内部控制变得不恰当，或对控制政策和程序遵循的程度降低，根据内部控 制审计结果推测未来内部控制的有效性具有一定风险。 XYZH/2025XAAA5B0175 金河生物科技股份有限公司 金河生物科技股份有限公司董事会： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我们审计 了金河生物科技股份有限公司（以下简称金河生物公司）2024 年 12 月 31 日财务报告内 部控制的有效性。 一、 企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部控制评 价指引》的规定，建立健全和有效实施内部控制，并评价其有效性是金河生物公司董事 会的责任。 二、 注册会计师的责任 我们的责任是在实施审计工作的基础上，对财务报告内部控制的有效性发表审计意 见，并对注意 ...

金河生物科技股份有限公司 2024 年度 审计报告 | 索引 | | 页码 | | --- | --- | --- | | 审计报告 | | 1-5 | | 公司财务报表 | | | | — | 合并资产负债表 | 1-2 | | — | 母公司资产负债表 | 3-4 | | — | 合并利润表 | 5 | | — | 母公司利润表 | 6 | | — | 合并现金流量表 | 7 | | — | 母公司现金流量表 | 8 | | — | 合并股东权益变动表 | 9-10 | | — | 母公司股东权益变动表 | 11-12 | | — | 财务报表附注 | 13-139 | 北 京 市 东 城 区 朝 阳 门 北 大 街 8号 富 华 大 厦 A座 9层 联系电话: telephone: +86(010)6554 2288 +86(010)6554 2288 ShineWing certified public accountants 9/F, Block A, Fu Hua Mansion, No.8, Chaoyangmen Beidaj ie, Dongcheng District, Beij ing ...

金河生物科技股份有限公司 2024 年度 募集资金年度存放与使用情况鉴证报告 | 索引 | | 页码 | | --- | --- | --- | | 鉴证报告 | | 1-2 | | 关于募集资金 2024 | 年度存放与使用情况的专项报告 | 1-7 | 我们认为，金河生物公司上述募集资金年度存放与使用情况专项报告已经按照深圳 证券交易所相关规定编制，在所有重大方面如实反映了金河生物公司 2024 年度募集资 金的实际存放与使用情况。 | 信永中和会计师事务所 北京市东城区朝阳门北大街 联系电话: +86 (010) 6554 2288 | | | --- | --- | | 8 号富华大厦 A 座 9 层 | telephone: +86 (010) 6554 2288 | | 9/F, Block A, Fu Hua Mansion, ShineWing | | | No.8, Chaoyangmen Beidajie, | | | Dongcheng District, Beijing, 传真: | +86 (010) 6554 7190 | | certified public accountant ...

Financial Performance - The company reported a basic earnings per share of 0.1294 yuan for 2024, an increase of 16.79% compared to 0.1108 yuan in 2023 [1] - The total revenue for 2024 was 23.71 billion yuan, reflecting a growth of 9.06% from 21.74 billion yuan in 2023 [1] - The net profit for 2024 reached 1 billion yuan, up by 16.28% from 0.86 billion yuan in 2023 [1] - The return on equity (ROE) improved to 4.50% in 2024, compared to 3.88% in 2023, marking a 15.98% increase [1] Shareholder Information - The top ten unrestricted shareholders collectively hold 33,877.83 million shares, accounting for 45.47% of the circulating shares, with an increase of 317.20 million shares from the previous period [1] - Inner Mongolia Jinhe Holdings Co., Ltd. remains the largest shareholder with 24,175.87 million shares, representing 32.45% of the total share capital, unchanged from the previous report [2] - New entrants in the top ten shareholders include Shenzhen Zetun Private Securities Fund Management Co., Ltd. and Baosheng Mixed Fund A, with holdings of 535.37 million shares and 414.06 million shares respectively [2] Dividend Distribution - The company announced a dividend distribution plan of 1 yuan per share (including tax) [2]

作为公司独立董事，本人未在公司兼任除董事会专门委员会召集人或者委员 以外的其他职务，与公司及其控股股东不存在可能妨碍本人进行独立客观判断的 关系，本人独立履行职责，不受公司控股股东或者其他与公司存在利害关系的单 位或个人的影响。本人具备《上市公司独立董事管理办法》《深圳证券交易所股 票上市规则》所要求的独立性，并按照监管规则进行了独立性自查，不存在影响 独立性的情况。 金河生物科技股份有限公司 2024 年度独立董事述职报告 本人作为金河生物科技股份有限公司（以下简称"金河生物"、"公司"） 独立董事，任职期间严格按照《中华人民共和国公司法》《上市公司独立董事管 理办法》等法律、法规以及《公司章程》《独立董事制度》等有关规定，认真履 行职责，积极的参加公司相关会议，认真审议董事会各项议案，对相关事项发表 了独立意见，充分发挥独立董事的独立性和专业性作用，切实维护公司及全体股 东尤其是中小股东的合法权益。现将 2024 年度履行独立董事职责汇报如下： 一、基本情况 （一）工作履历、专业背景及兼职情况 卢文兵：1967 年出生，中国籍，无境外居留权。研究生学历。现任内蒙古民 丰种业有限公司董事长，内蒙古腾格里投资 ...

关于独立董事独立性情况的专项意见 金河生物科技股份有限公司董事会 关于独立董事独立性情况的专项意见 1 根据《上市公司独立董事管理办法》《深圳证券交易所上市公司自律监管指 引第 1 号——主板上市公司规范运作》等要求，金河生物科技股份有限公司（以 下简称"公司"）董事会，就公司在任独立董事郭晓川先生、卢文兵先生、谢晓 燕女士的独立性情况进行核查、评估并出具如下专项意见： 经核查独立董事郭晓川先生、卢文兵先生、谢晓燕女士的任职经历以及签署 的相关自查文件，上述人员未在公司担任除独立董事以外的任何职务，也未在公 司主要股东公司担任任何职务，与公司以及主要股东之间不存在利害关系或其他 可能妨碍其进行独立客观判断的关系，不存在影响独立董事独立性的情况。因此， 公司独立董事符合《上市公司独立董事管理办法》《深圳证券交易所上市公司自 律监管指引第 1 号——主板上市公司规范运作》中对独立董事独立性的相关要求。 金河生物科技股份有限公司 董 事 会 2025 年 4 月 25 日 ...

Financial Performance - The company's operating revenue for 2024 reached ¥2,370,626,965.11, representing a 9.04% increase compared to ¥2,174,131,033.42 in 2023[6]. - The net profit attributable to shareholders for 2024 was ¥100,200,680.03, marking a 15.90% increase from ¥86,457,012.48 in 2023[6]. - The cash flow from operating activities for 2024 surged to ¥498,423,937.19, a significant increase of 150.76% from ¥198,765,852.62 in 2023[6]. - The basic earnings per share for 2024 was ¥0.1294, up 16.79% from ¥0.1108 in 2023[6]. - The total assets at the end of 2024 amounted to ¥5,650,587,583.04, reflecting a 3.61% increase from ¥5,453,807,416.04 at the end of 2023[6]. - The veterinary chemical drug segment generated revenue of 1,234.27 million yuan, a year-on-year increase of 21.47%, accounting for 52.06% of total revenue[59]. - The gross margin for veterinary chemical drugs improved to 40.17%, an increase of 7.40 percentage points from the previous year[59]. - The company achieved a revenue of 2,370.63 million yuan in 2024, representing a year-on-year growth of 9.04%[57]. - Net profit attributable to shareholders increased to 100.20 million yuan, up by 15.90% compared to the previous year[57]. - The veterinary biological products segment achieved revenue of 343.68 million yuan, a year-on-year increase of 2.58%, while the cost of goods sold increased by 27.45%[67]. Market Expansion and Strategy - The company is expanding its market presence, with a focus on both domestic and international markets, including key regions like the United States, Canada, and Southeast Asia[47]. - Future growth is anticipated in the veterinary vaccine sector, which is expected to become a high-growth area for the company[41]. - The company aims to enhance its R&D capabilities to meet the urgent demand for new products and technologies in the veterinary industry[29]. - The company is actively pursuing market expansion strategies, including potential acquisitions to strengthen its portfolio[109]. - The company plans to continue investing in R&D to enhance its core competitiveness despite the decrease in capitalized R&D expenditures[99]. - The company is focusing on expanding its pet medication product line to capitalize on the growing pet economy[152]. - The company plans to enhance its vaccine production capacity at the Jilin facility, with a planned capacity of 200 million doses, up from the current 100 million doses[75]. - The company is strategically developing an African swine fever vaccine in collaboration with well-known research institutions, indicating a significant market opportunity[74]. Research and Development - The company is focusing on R&D innovation, with several new vaccines and products in the pipeline, including a new inactivated vaccine for pigs and a new vaccine for cattle[68]. - The company is developing a new vaccine for African swine fever, expected to receive a new veterinary drug certificate by December 2026[97]. - The company is in the laboratory research phase for a new bovine respiratory disease vaccine, with a broad application prospect[97]. - The company is working on a dual inactivated vaccine for swine fever and pseudorabies, with registration expected after several trials[98]. - The company is developing a four-in-one inactivated vaccine for cats, with a market outlook from July 2024 to June 2029[98]. - The company has established two major R&D centers for animal vaccines, enhancing its global R&D capabilities and fostering innovation in vaccine development[51]. - The company is investing in vaccine R&D despite the long cycles and high costs, recognizing the inherent uncertainties in the outcomes[156]. Corporate Governance and Management - The company emphasizes that the operational plans and targets for 2025 and beyond are planning matters and do not constitute a substantive commitment to investors, highlighting the need for risk awareness[4]. - The company has established a comprehensive information disclosure system, ensuring that all relevant financial documents are available to stakeholders[15]. - The company maintains independence from its controlling shareholders, ensuring autonomous operations[164]. - The company has established an independent financial department and internal audit department, ensuring no shared bank accounts with controlling shareholders[169]. - The company has a complete and independent business system, with no reliance on shareholder assets for operations[170]. - The board of directors convened 12 meetings, maintaining effective governance and oversight[165]. - The supervisory board met nine times, ensuring compliance and protecting shareholder interests[165]. - The company held three shareholder meetings during the reporting period, ensuring compliance with legal requirements[163]. Production and Capacity - The company has increased its production capacity by 60,000 tons, equivalent to a 15% increase in the production of the core product, the chlortetracycline premix[39]. - The production capacity for the main product, Chlortetracycline, is currently 55,000 tons/year, with a new project expected to add an additional 60,000 tons/year, significantly enhancing production capacity[55]. - The company has established four production bases and two research centers, enhancing its competitive edge in the animal health industry[40]. - The company's new intelligent factory is expected to reduce production costs and improve fermentation efficiency, strengthening market competitiveness[39]. Financial Management - The company reported a significant increase in the gross margin of corn starch sales despite a decline in sales volume due to lower corn prices, contributing to higher overall profitability[78]. - The company reported an increase in interest expenses due to a rise in interest-bearing liabilities[57]. - The total procurement amount from the top five suppliers was ¥258,196,423.96, representing 15.67% of the annual procurement total[93]. - The company has established a fundraising management system to ensure compliance with relevant laws and regulations, protecting investors' interests[132]. - The company has implemented strict approval procedures for expenditures related to the raised funds[132]. Risks and Challenges - The company acknowledges risks from downstream industry fluctuations, particularly in the livestock sector, which directly impacts revenue[156]. - The company faces risks from rising raw material and energy prices, which could affect profit margins on veterinary chemical products[156]. - The company is addressing the complexities of the international trade environment, which may increase export costs and impact operations[157]. Employee and Training - The total number of employees at the end of the reporting period is 2,476, with 1,299 in the parent company and 1,177 in major subsidiaries[197]. - The company conducted 121 internal training sessions throughout the year, with approximately 8,863 participants, focusing on operational procedures, GMP regulations, and EHS knowledge[200]. - The company has established a comprehensive salary system based on regional salary levels and its own characteristics, combining basic salary and performance-based pay[199]. Shareholder Engagement - The annual shareholders' meeting had a participation rate of 36.01% on May 20, 2024, indicating active shareholder engagement[171]. - The first extraordinary shareholders' meeting of 2024 had a participation rate of 38.49% on August 6, 2024, reflecting continued investor interest[171]. - The company has implemented a share repurchase program, with a focus on restricted stock incentives[172].